Coptidis rhizoma and evodiae fructus against lipid droplet deposition in nonalcoholic fatty liver disease‐related liver cancer by AKT

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world. NAFLD has become one of the major factors contributing to hepatocellular carcinoma (HCC) development. However, there are no clear targets and therapeutic drugs for NAFLD‐related liver cancer. This study explored the active compounds, target and mechanism of coptidis rhizoma and evodiae fructus in the treatment of NAFLD‐related liver cancer based on the network pharmacology and experimental verification. There were 455 intersection targets of NAFLD‐related liver cancer, and 65 drug‐disease common targets. AKT1 has the highest degree, indicating that it may be a key target of coptidis rhizoma and evodiae fructus in the treatment of NAFLD‐related liver cancer. The expression level of AKT1 was high in high‐risk group, and the overall survival rate was lower than that in low‐risk group. After oleic acid induction, p‐AKT expression and lipid droplet deposition were promoted in HepG2 cells. Quercetin and resveratrol reduced lipid droplet deposition in vivo. Moreover, quercetin inhibited p‐AKT expression, resveratrol both reduced the expression of p‐AKT and AKT. The overall findings suggested that quercetin inhibited AKT in the treatment of NAFLD‐related liver cancer.

Regulation of UCP2 in nonalcoholic fatty liver disease: From mechanisms to natural product

“…Thus, the expression of CPT1α was up-regulated, the function of mitochondrial fatty acid βoxidation was enhanced, and finally, the steatosis of hepatocytes was improved Li, Li, Yang, et al, 2022). In addition, our previous studies also found that quercetin can improve lipid deposition in HepG2 cells by reducing the phosphorylation level of AKT (Li et al, 2023).…”